Access Course

Drs Emens and Adams discuss the emerging data for checkpoint inhibition in both the metastatic and neoadjuvant disease settings for TNBC.

This activity is intended for oncologists, obstetricians/gynecologists, and other healthcare professionals involved in the treatment of patients with triple-negative breast cancer (TNBC).

The goal of this activity is to increase understanding of the latest advances in the use of immunotherapy for the treatment of TNBC.

Learning Objectives:

• Have increased knowledge regarding the biologic rationale for using immune checkpoint inhibitors (ICIs) to manage patients with TNBC.
• Have increased knowledge regarding the emerging clinical trial data on the use of ICIs in the management of TNBC
• Have increased knowledge regarding the ongoing clinical trials that may affect standards of care across the treatment continuum for TNBC

Approximate Time to Complete: 30 minutes

Credit Available: Mar. 22, 2020 - Mar. 22, 2021

Developed through a partnership between SITC and Medscape.

Additional Resources for Clinicans from SITC:

View Available Guidelines Here.